Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.62 USD

0.62
794,416

+0.02 (3.06%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $0.62 0.00 (-0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.

Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher

by Zacks Equity Research

Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.

aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

by Zacks Equity Research

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $21.23, marking a +1.34% move from the previous day.

Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

by Ekta Bagri

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMRN) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

by Zacks Equity Research

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

Amarin Gains on FDA Approval of Vascepa Label Expansion

by Zacks Equity Research

Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.

Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMRN) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

by Zacks Equity Research

The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.

Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Top Ranked Momentum Stocks to Buy for November 27th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th.

Amarin's Shares Down on Underperform Rating by Oppenheimer

by Zacks Equity Research

Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

Will Amarin Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Amarin.

Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

by Zacks Equity Research

Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

What Makes Amarin (AMRN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMRN) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3

by Zacks Equity Research

Amarin beats estimates for both earnings and revenues in the third quarter of 2019. Shares up.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.